Skip to main content

Table 2 Efficacy endpoints at Week 24

From: A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin

Parameter Omarigliptin N = 153 Placebo N = 153
HbA1c, %
 Baseline 8.5 ± 0.8 8.6 ± 0.8
 Week 24 7.7 ± 1.1 8.4 ± 1.1
 Change from baselinea −0.67 (−0.84, −0.50) −0.06 (−0.23, −0.12)
 Change vs. placebob −0.61d (−0.85, −0.38) –
FPGc, mmol/L
 Baseline 10.2 ± 2.3 10.2 ± 2.3
 Week 24 8.9 ± 2.2 9.8 ± 2.0
 Change from baselinea −1.1 (−1.5, −0.7) −0.2 (−0.6, 0.2)
 Change vs. placebob −0.9d (−1.4, −0.4) –
  1. Values are mean ± standard deviation unless otherwise noted
  2. aLeast squares (LS) mean (95% CI)
  3. bDifference in LS means (95% CI)
  4. cTo convert to mg/dL multiply mmol/L value by 18
  5. dp < 0.001
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us